Cargando…

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis

Inhibition of deacetylases represents a new treatment option for human cancer diseases. We applied the novel and potent pan-deacetylase inhibitor panobinostat (LBH589) to human hepatocellular carcinoma models and investigated by which pathways tumor cell survival is influenced. HepG2 (p53wt) and Hep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Fazio, Pietro, Schneider-Stock, Regine, Neureiter, Daniel, Okamoto, Kinya, Wissniowski, Till, Gahr, Susanne, Quint, Karl, Meissnitzer, Matthias, Alinger, Beate, Montalbano, Roberta, Sass, Gabriele, Hohenstein, Bernd, Hahn, Eckhart G., Ocker, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2010
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619232/ https://www.ncbi.nlm.nih.gov/pubmed/20208142 http://dx.doi.org/10.3233/CLO-2010-0511

Ejemplares similares

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
por: Zopf, Steffen, et al.
Publicado: (2012)

Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report
por: Gahr, Susanne, et al.
Publicado: (2012)

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer
por: Di Fazio, Pietro, et al.
Publicado: (2016)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications
por: Klieser, Eckhard, et al.
Publicado: (2019)

bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells
por: Okamoto, Kinya, et al.
Publicado: (2007)

Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma
por: Wirries, André, et al.
Publicado: (2018)

Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
por: Singh, Avineesh, et al.
Publicado: (2016)

Influence of Five Potential Anticancer Drugs on Wnt Pathway and Cell Survival in Human Biliary Tract Cancer Cells
por: WACHTER, Julia, et al.
Publicado: (2011)

Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells
por: Montalbano, Roberta, et al.
Publicado: (2016)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells
por: Yan-Fang, Tao, et al.
Publicado: (2015)

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
por: Tate, Chandra R, et al.
Publicado: (2012)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
por: Korfei, Martina, et al.
Publicado: (2018)

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat
por: Zuwala, Kaja, et al.
Publicado: (2016)

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
por: Garrett, Leslie A., et al.
Publicado: (2016)

Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model
por: Phi, Ji Hoon, et al.
Publicado: (2017)

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
por: Cheng, Tiewei, et al.
Publicado: (2021)

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
por: Afolabi, Lukman O., et al.
Publicado: (2021)

The Histone Deacetylase Inhibitor LBH589 (Panobinostat) Modulates the Crosstalk of Lymphocytes with Hodgkin Lymphoma Cell Lines
por: Klein, Jan M., et al.
Publicado: (2013)

Overview of Major Classes of Plant-Derived Anticancer Drugs
por: Amin, Amr, et al.
Publicado: (2009)

Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
por: Neureiter, Daniel, et al.
Publicado: (2019)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
por: Jin, Ning, et al.
Publicado: (2016)

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
por: Redic, Kimberly A, et al.
Publicado: (2016)

DDEL-10. A NANOPARTICLE PLATFORM FOR INTRATHECAL DELIVERY OF THE HISTONE DEACETYLASE INHIBITOR (HDACi) PANOBINOSTAT IN METASTATIC OR RECURRENT MEDULLOBLASTOMA
por: Chaudhuri, Sauradip, et al.
Publicado: (2020)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
por: Harttrampf, Anne Catherine, et al.
Publicado: (2021)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

OR05-06 Histone Deacetylase Inhibitor, Panobinostat, In Combination With A Smac-mimetic For The Treatment Of Ovarian Granulosa Cell Tumours
por: Chu, Simon, et al.
Publicado: (2023)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future
por: Ocker, Matthias, et al.
Publicado: (2021)

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?
por: Ellinghaus, Peter, et al.
Publicado: (2022)

Fibromyalgia syndrome: metabolic and autophagic processes in intermittent cold stress mice
por: Oezel, Lisa, et al.
Publicado: (2016)

Epigenetic Regulation of p21(cip1/waf1) in Human Cancer
por: Ocker, Matthias, et al.
Publicado: (2019)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Biliary tract cancer stem cells - translational options and challenges
por: Mayr, Christian, et al.
Publicado: (2017)

Benign lesions that mimic cancer: Ovarian
por: Forstner, Rosemarie, et al.
Publicado: (2015)

Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
por: Bekric, Dino, et al.
Publicado: (2023)

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
por: Hamberg, Paul, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gv9c4p4n0t7ccvi0n5gtphntvl